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Novel thromboresistant materials
Sumanas W. Jordan and Elliot L. Chaikof, MD, PhD, Atlanta, Ga
The development of a clinically durable small-diameter vascular graft as well as permanently implantable biosensors and
artificial organ systems that interface with blood, including the artificial heart, kidney, liver, and lung, remain limited by
surface-induced thrombotic responses. Recent breakthroughs in materials science, along with a growing understanding
of the molecular events that underlay thrombosis, has led to the design and clinical evaluation of a variety of biologically
active coatings that inhibit components of the coagulation pathway and platelet responses by surface immobilization or
controlled release of bioactive agents. This report reviews recent progress in generating synthetic thromboresistant
surfaces that inhibit (1) protein and cell adsorption, (2) thrombin and fibrin formation, and (3) platelet activation and
aggregation. (J Vasc Surg 2007;45:104A-115A.)Despite advances in surgical technique, antithrombotic
pharmaceutical regimens, and biomaterials science, there
remains a need for synthetic bypass grafts that can perform
superior to or even comparable with autologous vein grafts.
Although 1-year patency rates of expanded polytetrafluo-
roethylene (ePTFE) prostheses and saphenous vein grafts
for above knee infrainguinal bypass are similar, by 5 years,
up to 60% of synthetic grafts will occlude or require revision
compared with 20% to 30% of vein grafts.1-7 This disparity
is even greater for bypass to the below knee popliteal artery
or infrageniculate vessels or in the performance of synthetic
arteriovenous dialysis grafts when compared with autolo-
gous fistulas.
Coronary artery stenting has likewise improved clinical
and angiographic outcomes compared with standard bal-
loon angioplasty,8,9 leading to 600,000 stents being
placed in the United States in 2004.10 However, a pooled
analysis of six recent clinical trials reported that stent reste-
nosis is associated with serious clinical consequences; for
example, a 64% incidence of myocardial infarction or death
has been noted at the time of stent thrombosis.11 Indeed,
ongoing concerns for an apparent increased risk of late
stent thrombosis among patients receiving drug-eluting
stents has tempered early enthusiasm for this technology,
particularly among patients with left main or triple-vessel
disease in which survival rates have been better for those
who undergo bypass surgery. In this regard, an effective
synthetic arterial substitute for coronary artery bypass graft-
ing has yet to be achieved, and the design of stent coatings
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104Afor drug elution with improved thromboresistance is a
desirable goal.
Finally, the development of a host of permanently
implanted artificial organ systems, including the artificial
heart, kidney, liver, and lung, remain limited primarily by
surface-related thrombotic responses that are accentuated
in small-caliber systems or in more complex flow geome-
tries that may be associated with local regions of recirculat-
ing flow. Although the failure of these devices is related to
maladaptive biologic reactions at both the blood–material
and tissue–material interface, these two events are interre-
lated. Thrombin generation and platelet activation contrib-
ute to intimal hyperplasia, and restenosis leads to reduced
flows that increase the risk of a thrombotic response. In this
article, we review progress in generating synthetic throm-
boresistant surfaces that inhibit (1) protein and cell adsorp-
tion, (2) thrombin and its formation, and (3) platelet
activation and aggregation.
INHIBITING PROTEIN AND CELL
ADSORPTION
The generation of nonfouling surfaces that resist pro-
tein adsorption and subsequent platelet deposition and
activation has been pursued within a framework that pos-
tulates that thermodynamic factors at the blood–material
interface drive protein adsorption. Specifically, protein ad-
sorption is favored by electrostatic and hydrophobic inter-
actions between the adsorbed protein and the synthetic
surface as well as by a local increase in entropy that occurs at
the displacement of water molecules and counter ions from
the first few nanometers of the material surface.12 Both
synthetic and natural materials, including poly(ethylene
oxide) (PEO), pyrolytic carbon, albumin, phosphorylcho-
line, and more recently, elastin-inspired protein polymers,
have been investigated in the development of strategies to
passivate the prosthetic surface by reducing or eliminating
enthalpic or entropic effects that drive protein and cell
adsorption on a molecular level.
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served that PEO passively adsorbed onto glass surfaces
prevented the adsorption of viruses, platelets, and throm-
bin. Subsequent studies have demonstrated that PEO has
among the lowest levels of protein or cellular adsorption of
any known polymer. This property was attributed to the
presence of a hydrophilic ether oxygen in its structural
repeat unit, [CH2-CH2-O]n, which leads to a water-sol-
vated structure that is capable of forming a “liquid-like”
surface with highly mobile molecular chains that exhibit no
systematic molecular order. Unlike other hydrophilic poly-
mers, such as poly(hydroxyethyl methacrylate) and poly-
acrylamide, the absence of surface charges and the presence
of only small hydrophobic methylene groups in the struc-
tural repeat unit was thought to provide few other sites for
protein or cellular binding.13
Surface modification with PEO has been attempted by
several methods, including bulk modification, covalent
grafting, and physical adsorption. In most cases, investiga-
tors have been able to demonstrate resistance to protein
binding in vitro. In vivo results have been inconsistent,
however, and clinical studies of a PEO-modified stent or
graft have yet to be performed. For the interested reader, a
comprehensive review of the blood compatibility of PEO
can be found in a monograph by Lee et al.14
Albumin-coated surfaces. Albumin as an inert,
thromboresistant coating has been pursued since early
studies of platelet interactions with various adsorbed pro-
teins on artificial surfaces established that albumin induced
significantly less platelet adhesion compared with other
plasma proteins, including fibrinogen and -globulin.15-18
Some groups have covalently grafted albumin to
surfaces,19-21 while others have modified surfaces with long
aliphatic chains (C8-C18) or PEO-tethered warfarin to in-
crease selective affinity for endogenous albumin.22-27
Guidoin et al28,29 developed a glutaraldehyde-
crosslinked albumin coating later manufactured by Bard.
The Bard albumin-coated Dacron prosthesis was evaluated
by Kotte-Marchant et al30 and displayed reduced platelet
and leukocyte adhesion and aggregation, as well as reduced
fibrin production in vitro. In a thoracoabdominal bypass
model in dogs, however, only small differences were ob-
served between coated and uncoated grafts.31 In clinical
studies, al-Khaffaf and Charlsworth32 and Kudo et al33
have evaluated this prosthesis in the aortic position, and its
performance characteristics were similar to other non-
coated vascular prostheses.
Pyrolytic carbon-coated surfaces. Pyrolytic, or gra-
phitic, carbon coating of implantable materials has been
investigated for a variety of blood-contacting devices, in-
cluding vascular grafts, heart valves, and stents.34-36 In
brief, pyrolytic carbon films are produced by chemical
vapor deposition in which a hydrocarbon, such as methane,
is heated to its decomposition temperature and the gra-
phitic layer is allowed crystallize as a highly ordered layer of
carbon atoms. Early animal studies of carbon-coated vascu-
lar prostheses demonstrated improved patency rates com-
pared with uncoated controls.37,38 However, surface irreg-ularities on carbon-lined ePTFE grafts have contributed to
poor performance in other investigations.39,40
More recently, 15-month implant studies in sheep doc-
umented reduced platelet adhesion and spreading on car-
bon-coated polyester grafts, but these observations did not
affect overall histologic outcomes or patency rates.41 Fur-
thermore, in a prospective, randomized multicenter study
conducted in Germany, 283 patients received 6-mm car-
bon-coated (Carboflow, C.R. Bard, Inc, Murray Hill, NJ.)
or uncoated ePTFE grafts (Bard, Inc) for femoral–anterior
tibial artery bypass. At 3-year follow-up, no significant
differences were observed between the two groups with
respect to patency or limb salvage.42
A preclinical investigation of Carbofilm-coated niti-
nol stents (Flype Carbostent, Sorin Biomedica Cardio,
Via Crescentino, Italy) implanted in porcine iliac arteries
and the nonrandomized Aspirin Alone Antiplatelet Reg-
imen After Intracoronary Placement of the Carbostent
(ANTARES) clinical trial of the Carbofilm-coated stainless
steel Carbostent (Sorin Biomedica Cardio, Via Cres-
centino, Italy) demonstrated acceptable biocompatibil-
ity.43,44 However, in the prospective, randomized Car-
bostent-trial conducted by Sick et al,45 the Carbofilm
coating did not significantly reduce rates of restenosis or
major adverse events compared with bare stainless steel
stents of the same design and delivery method.
Likewise, in the Prevention of Recurrent Venous
Thromboembolism (PREVENT) trial, investigators ob-
served no difference between carbon-coated and bare stain-
less steel MAC stents (amg, Int, GmbH, Raesfeld-Erle,
Germany).46 Finally, initial and long-term outcomes in the
Asian Pacific Multicenter Arthos Stent Study (PASS) were
similar for a stent implanted with carbon ions and its
bare-metal counterpart.47
Phosphorylcholine surfaces. Planar-supported lipid
bilayers composed of phosphatidylcholine, the predomi-
nant glycerophospholipid found in animal cell membranes,
have been shown to limit protein and cell adhesion in
vitro.48-52 It has been proposed that this phenomenon is
due to the zwitterionic nature of the phosphorylcholine
head group that while carrying both positive and negative
charges is electrically neutral at physiologic pH. Applica-
tions of supported lipid films as coatings for implantable
devices have been limited by the inherent instability of a
coating that is formed by individual molecules that “self-
assemble” as a monolayer or bilayer film through relatively
weak hydrophobic van der Waal interactions.53
As a consequence, methods have been developed to
create stable “membrane-mimetic” films through protein
anchors,54,55 heat stabilization,56 and in situ polymeriza-
tion of synthetically modified polymerizable phospholip-
ids57-62 (Fig 1). The protein and cell-resistant properties of
the exposed phosphatidylcholine layer were retained in all
of the studies. Our group recently applied a polymerized
membrane-mimetic film onto the luminal surface of a
4-mm-diameter ePTFE vascular prosthesis and demon-
strated dramatically reduced platelet adhesion in a baboon
femoral arteriovenous shunt model.63 An alternate ap-
TFE
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ical grafting of the phosphatidylcholine-head group to the
metal or polymer surface.49,64-67 Since 1984, a variety of
polymethacrylate and polyurethane-based polymers have
been synthesized that incorporate the phosphorylcholine
head group within the polymer backbone.68,69
Yoneyama et al70-72 demonstrated excellent in vivo
blood compatibility of a segmented poly(etherurethane)/
2-methacryloyloxyethyl phosphorylcholine (MPC) poly-
mer blend processed as a coating for Dacron prostheses.
Chen et al73-74 evaluated 4-mm-diameter ePTFE grafts
coated with a copolymer of MPC and lauryl methacrylate
(LM) in a canine femoral arteriovenous shunt and demon-
strated significantly reduced platelet deposition and limited
neointimal hyperplasia at anastomotic sites. Whelan et
al75,76 noted favorable results in a porcine coronary angio-
plasty model for BiodivYsio stainless steel stents (Biocom-
patibles, Ltd, Surrey, United Kingdom) dip-coated with a
MPC/LM polymer.
However, studies of phosphorylcholine polymer–
coated Palmaz-Schatz stents (PS 153, Johnson and John-
son Interventional, Warren, NJ; BCP Dilatec, Surrey,
Fig 1. Top, Scheme illustrates in situ polymerization
mimetic” thin film. A and B, Scanning electron microgr
inner lumen of an ePTFE vascular graft. Scale bar inA is
(Adapted from Jordan SW, Faucher KM, Caves JM, Apka
membrane-mimetic film on the luminal surface of an ePUnited Kingdom) revealed no advantage for coated stentscompared with bare-metal stents in both rabbit iliac and
porcine coronary angioplasty models.77 Early clinical expe-
rience with the BiodivYsio (Biocompatibles Ltd, Surrey,
United Kingdom) has been associated with acceptable re-
sults, but randomized prospective trials have not confirmed
the unique benefit of the phosphorylcholine coating
alone.78
Elastin-inspired polymer surfaces. The pursuit of
elastin as a coating for blood-contacting materials has been
motivated by the observation that as a constituent struc-
tural protein of the vascular wall, elastin elicits minimal
platelet adhesion and aggregation.79,80 Ito et al81 initially
coated Dacron vascular grafts with tissue-derived elastin
and noted inhibition of smooth muscle cell migration
without an effect on endothelial cell motility, which sug-
gested that such a coating might inhibit the formation of
anastomotic intimal hyperplasia.
The intrinsic insolubility of elastin has made this pro-
tein difficult to purify and process when derived from
bovine or porcine tissue, however. This limitation has been
largely overcome by the structural characterization of elas-
phospholipid surface assembly to form a “membrane-
f a membrane-mimetic thin film that was coated on the
m and in B 38.5 m. FITC, Fluorescein isothiocyanate.
RP, Rele SS, Sun XL, et al. Fabrication of a phospholipid
vascular graft. Biomaterials 2006;27:3473-81).of a
aphs o
385 
riantin with the identification of consensus sequences that have
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elastin-inspired protein polymers.82-85
Defife et al86 photochemically linked soluble and
crosslinked poly(VPGVG) to silicone through amino-ter-
minal lysine residues and demonstrated reduced fibrinogen
and immunoglobulin adsorption in vitro as well as de-
creased release of proinflammatory cytokines by mono-
cytes.86 Recently, Woodhouse et al87 passively adsorbed a
recombinant elastin polypeptide (EP20-24-24) that con-
sists of exons 20, 21, 23, and 24 of the human elastin gene
onto synthetic surfaces and observed decreased platelet
deposition and activation in vitro and delayed catheter
occlusion in vivo. Consistent with these investigations, we
have synthesized a novel recombinant elastin-mimetic pro-
tein polymer and observed minimal thrombogenicity when
it was examined as a thin film on 4-mm-diameter ePTFE
grafts in an acute primate ex vivo shunt model88 (Fig 2).
INHIBITING THROMBIN AND FIBRIN
FORMATION
The endothelial cell presents and releases a number of
biologically active constituents that limit thrombotic re-
sponses. As such, seeding or otherwise reconstituting en-
dothelial cells on a prosthetic surface has been actively
pursued as a strategy for generating thromboresistant vas-
cular substitutes. This approach, however, poses its own
challenges related to cell sourcing, stability, viability, and
function that have been detailed elsewhere.89-91 Alterna-
tively, promising results have been achieved through bio-
logically inspired or biomimetic designs in which anti-
thrombogenic features of the endothelial cell surface are
selectively mimicked by introducing bioactive molecules
such as heparin, thrombomodulin, or urokinase92-95 onto
the surface of synthetic materials.
Heparin. The first report of a heparinized surface was
published in 1963 by Gott et al,35 who demonstrated
significantly prolonged in vitro and in vivo clotting times
on graphite-coated surfaces ionically bonded with heparin.
Since then, heparin-coating technologies have been devel-
Fig 2. A, Scheme illustrates an ex vivo femoral arteriov
model. B, Platelet deposition normalized by surface a
polytetrafluoroethylene. C, Macroscopic photographs of
after coating with a recombinant elastin protein polym
Apkarian RP, Hanson SR, Chaikof EL. The effect of a rec
acute thrombogenicity in a baboon arteriovenous shuntoped for a number of blood-contacting devices and usedmost extensively in cardiopulmonary bypass circuits96,97
(Fig 3).
The literature on heparin immobilization is extensive
and has been reviewed elsewhere.98-100 Briefly, techniques
to immobilize heparin include but are not limited to elec-
trostatic self-assembly through heparin’s negatively
charged sulfate groups,101,102 covalent grafting (often by a
spacer arm),103-107 integration into a hydrogel network,108
and loading into a bulk polymer for controlled release.109
One technique that has been successfully translated to the
clinic is end-point immobilization, in which the reducing
end of the linear heparin chain is depolymerized to yield a
reactive aldehyde group that can then be conjugated to a
primary amine on the graft or stent surface.110-112
Although a randomized, prospective clinical study of
heparin-bonded Dacron grafts in the femoropopliteal po-
sition showed no significant improvement compared with
uncoated ePTFE at 5 years,113 an ePTFE prosthesis coated
with end-point immobilized heparin (Propaten graft, W. L.
Gore & Associates, Flagstaff, Ariz) has been recently devel-
oped and has renewed interest in the performance of hep-
arin-coated grafts. A preclinical animal study in greyhound
dogs demonstrated a significant reduction in acute and
chronic thrombogenicity of heparin-bonded grafts with
retention of heparin bioactivity at 12 weeks.114 Platelet
deposition and anastomotic neointimal hyperplasia were
also reduced in ex vivo femoral arteriovenous shunt and
chronic aortoiliac bypass models, respectively.115 Heyligers
et al116 have also documented reduced fibrinopeptide A
production with absent platelet or fibrin adhesion when
non-anticoagulated blood from healthy donors was drawn
directly into heparin-bonded grafts.
Nonrandomized clinical studies have reported 1-year
primary patency rates of 84% to 91% for above knee bypass
grafts and 81% to 92% for below knee bypass grafts.117-119
Two-year primary patency rates are 68% to 76% for
above knee bypasses and 73% to 81% for below knee
bypasses.117-119 Given the similarity of these early results
with previously reported patency rates for uncoated ePTFE
s shunt to assess platelet deposition in a baboon animal
ver a 1-hour time period (n  6). ePTFE, Expanded
ained (left) and Coomassie-stained (right) graft samples
. (Adapted from Jordan SW, Haller CA, Sallach RE,
inant elastin-mimetic coating of an ePTFE prosthesis on
aterials 2007;28:1191-7).enou
rea o
unst
er film
ombbypass grafts, prospective randomized trials are warranted
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The importance of randomized clinical trials is empha-
sized by the experience with heparin-coated coronary stents
and cardiopulmonary bypass circuits. Promising preclinical
reports120 and early nonrandomized clinical trials did not
result in improved clinical or angiographic outcomes when
heparin-coated stents were compared with bare-metal
stents in two prospective, randomized clinical stud-
ies.121,122
Likewise, Edmunds and Colman123 have noted that
neither covalent nor ionic-bonded heparin-coated cardio-
pulmonary perfusion circuits reduce the rate of thrombin
formation, protect platelets, or reduce postoperative bleed-
ing or transfusion requirements. They note that that hepa-
rin-coated circuits appear to reduce some biochemical as-
pects of the inflammatory response, but a clinical benefit
has not been documented. Administration of protamine
should be avoided, because it will inactivate the heparin
coating.
Direct thrombin inhibitors. Although they are not a
natural constituent of endothelial cells, direct thrombin
inhibitors such as recombinant hirudin and argatroban have
been used to functionalize surfaces. Seifert et al124 have
used glutaraldehyde to crosslink hirudin to poly(D,L-lac-
tide-co-glycolide), LoGerfo et al125-129 have grafted re-
combinant hirudin to polyurethane and Dacron by using a
crosslinked-modified albumin base coat, and Lahann et
al130 have functionalized nitinol stents with recombinant
hirudin.
Thrombomodulin. Several investigators have immo-
bilized thrombomodulin onto polymeric surfaces to gener-
ate surfaces that actively limit the local generation of
Fig 3. A, Rate of thrombin generation as a function of
(‘) or non-heparin containing () surfaces in the prese
initiated by tissue factor deposited in a spatially confin
absence of surface-bound heparin or antithrombin III is
a standard error 10% (n  5). When compared with th
effect of surface bound heparin in inactivating thrombin
initiated by activation of factor XII by plasma proteins ad
heparin. However, antithrombin III bound to heparin-co
surface bound heparin is ineffective in the inactivation o
such as Va and VIIIa. Moreover, heparin coated surfaces
thrombin produced by the extrinsic coagulation path
anastomotic sites, inflammatory cells, or as a circulating
Chaikof EL.Membrane-mimetic films containing thromb
generation in a flow model. Biomaterials 2006;27:2637thrombin through the production of activated protein Crather than inactivate thrombin after it has already been
produced. Specifically, activated protein C inactivates fac-
tors Va and VIIIa, thereby limiting Xa and thrombin pro-
duction.
Kishida et al131-133 conjugated recombinant human
thrombomodulin to both aminated and carboxylated sur-
faces, including poly(vinyl amine) and poly(acrylic acid)
surface-grafted polyethylene, and a surface-hydrolyzed
poly(ether urethaneurea). Similarly, Vasilets et al134 re-
ported binding thrombomodulin onto poly(acrylic acid)
surface-grafted PTFE. As an alternate approach, Cutler et
al135 physically adsorbed and crosslinked soluble human
thrombomodulin onto small-caliber ePTFE grafts and re-
ported promising short-term results in vivo. Other investi-
gators, such as Sperling et al136,137 and Han et al,138 have
tethered thrombomodulin to surfaces by using a polyeth-
ylene glycol spacer.
A disadvantage of all of these strategies is the inherent
reduction in bioactivity that is associated with immobiliza-
tion schemes that involve reactions to any freely available
amino or carboxyl functionality on the protein surface,
including those near or within the catalytic site of the
protein.
We recently used genetically directed synthesis to cre-
ate a recombinant thrombomodulin construct composed
of the catalytically active site along with a C-terminal syn-
thetic, non-natural amino acid, azido(N3)-methionine.
The thrombomodulin construct functionalized with azi-
do(N3)-methionine can be coupled to surfaces directly
through the C-terminus by using highly selective reaction
schemes, with full retention of bioactivity139,140 (Fig 4). As
an additional strategy, we have also produced membrane-
mimetic surface assemblies containing thrombomodulin
sion time at a wall shear rate of 50/s on heparin-bound
f antithrombin III (ATIII). Thrombin production was
stream zone. The rate of thrombin production in the
rated (●). Each data point represents a mean value with
ect of circulating antithrombin III alone, the additional
ll. B, The contact pathway of the coagulation cascade is
d onto a biomaterial surface, as well as by surface bound
surfaces inactivates IXa, Xa, and thrombin. Nonetheless,
nflammatory and procoagulant precursors of thrombin,
t provide an efficient scheme for inactivating fluid phase
initiated by the presence of tissue factor present at
ble factor. (Adapted from Tseng PY, Rele SS, Sun XL,
dulin and heparin inhibit tissue factor-induced thrombin
).perfu
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bomodulin to dramatically reduce thrombin production
induced by tissue factor has been characterized under both
simulated venous and arterial flow conditions in vitro.143
INHIBITING PLATELET ACTIVATION
Recent clinical studies have highlighted the importance
of antiplatelet therapy after vascular intervention. In a
randomized study comparing antiplatelet with anticoagu-
lant therapy after the placement of Palmaz-Schatz stents,
Schomig et al144 demonstrated that antiplatelet therapy
was associated with a lower incidence of cardiac events and
hemorrhagic complications. It has also become standard
practice to administer aspirin and a purinergic antagonist,
such as clopidogrel, after coronary stenting.145-148
The roles of clopidogrel or ticlopidine have not been
assessed in vascular grafts, but the capacity of aspirin to
reduce thrombosis of ePTFE vascular prostheses has been
noted in a number of randomized trials.149 Prolonged
systemic administration of all antiplatelet drugs signifi-
cantly increases the risk of bleeding and gastrointestinal
complications, however. Clopidogrel has also been associ-
ated with myelotoxicity, although infrequently, and other
untoward side effects may be discovered as clinical trials
proceed to investigate longer durations of therapy.150-153
This section will discuss the development of materials that
locally inhibit platelet activity by surface immobilization of
antiplatelet molecules, such as prostacyclin, or local delivery
of antiplatelet agents, including nitric oxide (NO).
A number of agents are available to block platelet
responses, and nearly all have been incorporated onto or
within surfaces that contact blood. Kidane et al154 have
reviewed anticoagulant and antiplatelet agents and their
mechanisms of action, with an added discussion of their
applicability to cardiovascular device development. Rele-
vant to this review, the oldest and most widely used inhib-
itor of platelet aggregation is acetylsalicylic acid (aspirin),
an irreversible cyclooxygenase inhibitor that interferes with
Fig 4. A, Scheme for site-specific linkage of a reco
alkyne-azide cycloaddition. PBS, Phosphate buffered sali
ing surfaces that produced activated protein C (APC)
procoagulant precursors of thrombin. Moreover, sinc
anticoagulant, it may provide a more efficient scheme f
(Adapted from Sun XL, Stabler CL, Cazalis CS, Chaik
surfaces by sequential Diels-Alder and azide-alkyne cyclothe arachidonic acid pathway, specifically, the synthesis ofthromboxane A2 by platelets. In contrast, the prostaglan-
dins (PGE1 and PGD2) and prostacyclin (PGI2), along
with their pharmacologic analogues, inhibit platelet activity
by raising intracellular cyclic adenosine monophosphate
(cAMP) through the stimulation of adenylate cyclase. Sim-
ilarly, dipyridamole increases cAMP by inhibition of cyclic
phosphodiesterase. Abciximab and related drugs block the
platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor on
activated platelets, thus preventing binding to fibrinogen
and, subsequently, platelet aggregation. Finally, NO re-
leased by endothelial cells prevents adhesion and activation
of platelets and may also limit intimal hyperplasia by inhib-
iting smooth muscle cell proliferation.155
Antiplatelet drugs. Several investigators have de-
scribed the direct immobilization of antiplatelet agents
onto polymeric surfaces. For example, Sharma et al156,157
have immobilized PGI2 and PGE1 onto albuminated sur-
faces with inhibition of platelet adhesion, and Chandy et
al64 have linked PGI2 and PGE1 to ePTFE and polyethyl-
ene terephthalate vascular grafts and also to glutaralde-
hyde-treated porcine pericardium for heart valve prosthe-
ses.158 Aldenhoff et al159-161 have conjugated
dipyridamole to polyurethane surfaces by a short hydro-
philic spacer and showed reduced platelet adhesion in vitro
and improved patency in a goat model.
Sharma et al have also synthesized aspirin-eluting
blood-contacting matrices,162,163 and Rodriguez et
al164,165 prepared bioresorbable polymer coatings with sus-
tained release of salicylic acid. When applied to the luminal
surface of both woven and knitted Dacron grafts, acute
platelet deposition decreased in a canine ex vivo model.166
Fontaine et al167 loaded polymer-coated Wallstents (Bos-
ton Scientific, Natick, Mass) with abciximab, implanted the
stents within canine iliac arteries, and noted reduced neo-
intimal thickness 6 weeks after implantation. Viscardi et
al168 impregnated ePTFE grafts (4 mm internal diameter)
with the prostacyclin analog iloprost by using alginate as a
delivery vehicle.168 Similarly, Alt et al169-171 developed
ant thrombomodulin (rTM) to a surface via “click”
EG, polyethylene glycol. B, Thrombomodulin-contain-
be more effective in inactivating proinflammatory and
C is released from the surface as a local fluid phase
activating thrombin produced by tissue factor present.
. Carbohydrate and protein immobilization onto solid
tions. Bioconjugate Chem 2006;17:52-57).mbin
ne; P
may
e AP
or in
of ELresorbable polylactic acid stent coatings that release hirudin
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erative effects. Although available pharmacologic agents
that inhibit platelet activation continue to increase, drug-
eluting strategies are inherently limited by the challenge of
a finite reservoir that limits the duration of activity.
Materials that release and generate nitric oxide.
Smith et al172,173 were the first to derivatize a polymeric
backbone with diazeniumdiolate groups ([N(O)NO]–) to
generate a NO-releasing polyethylenimine coating for
blood-contacting applications. The functionalized polymer
demonstrated antiproliferative activity against rat aortic
smooth muscle cells and antiplatelet activity in a baboon
extracorporeal shunt. NO release was sustained for up to 5
weeks in vitro. In addition, Keefer et al174,175 have devel-
oped piperazine as a linker for coupling diazeniumdiolate
groups to other biologically relevant molecules, including
phospholipids and polysaccharides. West et al176,177 have
synthesized PEO hydrogels and polyurethane films func-
tionalized with various NO donor groups that were able to
produce NO for approximately 2 months in vitro. In all
cases, smooth muscle proliferation and platelet activation
were reduced.
Meyerhoff et al178-182 have synthesized a variety of
hydrophilic and hydrophobic diazeniumdiolates as NO
donors. In the course of these investigations, they noted
that diamine precursors that leached into the surrounding
media could react to form carcinogenic nitrosamines.178 As
a consequence, the focus shifted to more lipophilic com-
pounds that generated fewer by products.183-185 Nonethe-
less, the capacity to release NO over a sustained period is
bound by a finite reservoir of NO donors. In response to
this limitation, Oh et al,186,187 along with other groups,188
have recently described catalytic agents that convert endog-
enous nitrites and nitrosothiols to nitric oxide, thereby
providing an approach for generating an extended flux of
NO (Fig 5).
CONCLUSIONS
A variety of innovative schemes have been proposed for
the development of blood-contacting films that eliminate
the risk of surface-induced thrombus formation. Designs
have been inspired by an enhanced appreciation of surface
and colloid sciences, the growing understanding of bio-
logic structure–function relationships that underlie coagu-
lation and platelet activation and aggregation, and the
related processes that inhibit these events. Coupled with
breakthroughs in polymer science, bio-organic and su-
pramolecular chemistry, engineering, and materials science
along with the ever-increasing availability of advanced tools
that are now capable of characterizing and manipulating
atomic and molecular scale features of designer surfaces,
the development of a durable, nonthrombogenic synthetic
interface is inevitable.
Admittedly, evaluating novel molecular materials in a
clinical setting is a potentially complex and costly enter-
prise. However, the growing number of protein-resistant
and cell-resistant modifications of stents and grafts that
have been recently evaluated highlight the significance ofbiomaterials science in clinical medicine and our capacity to
carefully evaluate these systems. The development of a
variety of biologically active coatings that inhibit compo-
nents of the coagulation pathway and platelet responses
either by surface immobilization or controlled release of
bioactive agents holds great promise, is rapidly evolving,
and their evaluation in a clinical setting is actively under-
way. The clinical impact of effective thromboresistant ma-
terials not only on the development of effective vascular
substitutes or endovascular prostheses but also in the de-
sign of permanently implantable sensors, transducers, and
artificial organ systems will be profound.
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